2010
Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial
Rosenheck R, Davis S, Covell N, Essock S, Swart M, Stroup S, McEvoy J, Lieberman J. Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2010, 8: 561-569. DOI: 10.1176/foc.8.4.foc561.Peer-Reviewed Original ResearchGreater weight gainNew medicationsOutcome measuresWeight gainNeurological side effectsAdditional outcome measuresPotential confounding factorsQuality of lifeStudy drugPrevious medicationCATIE trialMultivariate adjustmentImprove OutcomesMedicationsSide effectsOlanzapinePatientsConfounding factorsDrugsHealth costsOutcomesSignificant differencesRisperidoneCATIEMixed models
2000
Acculturation and the Lifetime Risk of Psychiatric and Substance Use Disorders among Hispanics
ORTEGA A, ROSENHECK R, ALEGRÍA M, DESAI R. Acculturation and the Lifetime Risk of Psychiatric and Substance Use Disorders among Hispanics. The Journal Of Nervous And Mental Disease 2000, 188: 728-735. PMID: 11093374, DOI: 10.1097/00005053-200011000-00002.Peer-Reviewed Original ResearchConceptsSubstance use disordersNational Comorbidity SurveyUse disordersLifetime riskGreater riskSubstance abuse disordersNon-Hispanic whitesMexican AmericansMultivariate adjustmentRisk factorsAbuse disordersPsychiatric disordersPsychiatric diagnosisIllness increasesSociodemographic characteristicsDSM-IIIU.S. adultsDisordersHispanic subgroupsAmerican SocietyParental nativityNational probability sampleRiskHispanicsProbability sample